RxDoctor Payments Data

Parvez Memon, MD

Family Medicine · Stroudsburg, PANPI 1225181811

Payments from drug & device makers

$6,941in general payments, 2019–2025

Across 432 payments — averaging $16.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • GSK$1K
  • Lilly USA, LLC$892
  • Boehringer Ingelheim$650
  • AstraZeneca$522
  • Amgen$361
  • plus $2K from 24 others

What the payments were for

  • Food & beverage$6,917100%
  • Education$240%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,941 in reported general payments places this provider in the 90th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$24,170
Medicare patients
105
Services billed
248

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide29$45,298
Trelegy ElliptaFluticasone/Umeclidin/Vilanter26$28,935
EliquisApixaban16$23,075
MounjaroTirzepatide19$22,027
JardianceEmpagliflozin19$20,676
RybelsusSemaglutide11$15,969
JanuviaSitagliptin Phosphate12$15,146
Lantus SolostarInsulin Glargine,hum.Rec.Anlog12$2,370
Albuterol Sulfate HfaAlbuterol Sulfate52$1,799
Ventolin HfaAlbuterol Sulfate13$1,173
Rosuvastatin Calcium71$804
Ezetimibe26$785
Oxycodone Hcl44$677
Novofine 32Pen Needle, Diabetic11$616
Losartan Potassium67$557

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,547$61,26740 claims
GSKTrelegy Ellipta$1,023$28,93526 claims
PfizerEliquis$267$23,07516 claims
Lilly USA, LLCMounjaro$892$22,02719 claims
Boehringer IngelheimJardiance$650$20,67619 claims
MerckJanuvia$302$15,14612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Stroudsburg

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →